drugset / Trial / NCT02357810
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Phase 2
Completed
178 enrolled
Northwestern University
GlaxoSmithKline · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2015-03-21
- Primary completion
- 2018-04-27
- Completion
- 2021-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | — | Oral |
| Subject | Topotecan | Small molecule | — | Oral |